• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
TREAT-NMD

TREAT-NMD

Advancing diagnosis, care and treatment for people with neuromuscular diseases around the world

Contact us

header-right

  • Home
  • Who We Are
    • About Us
    • Partnerships and Collaborations
    • Governance
    • Our Team
  • Who We Support
    • Patients
    • Clinicians / Researchers
    • Life Sciences Industry
  • What We Do
    • Advisory Committee for Therapeutics
    • The Global Registry Network
    • Core Datasets
    • Education
    • Post-Marketing Surveillance
  • Resources and Support
    • Neuromuscular Disease Information
    • Research Overview
    • Standards of Care & Family Guides
    • SOP Library
    • Social and Ethical Issues
  • Connect With Us
    • News
    • Events
    • Submit an Event
    • Newsletter Sign-up
    • Network Membership
    • Contact Us

Global Data systems Oversight Committee – TGDOC

Home / What We Do / Global Data systems Oversight Committee – TGDOC

Global Data systems Oversight Committee – TGDOC

The TREAT-NMD Global Data systems Oversight Committee (TGDOC) includes Member Registry Curators, Patient Representatives, and representatives of the TREAT-NMD Ethics Board.  It is governed by an Executive Board, comprised of the TREAT-NMD Services CEO, the TREAT-NMD Global Enquiries Manager and TREAT-NMD Global Registries Support Assistant. All members are required to sign Confidential Disclosure Agreements (CDAs). 

TGDOC is responsible for reviewing requests for data or recruitment support from the Global Registries Network. A streamlined procedure is in place to ensure approvals for data aren’t delayed – TGDOC can usually make an initial approval of whether a data request should proceed within 14 days. 

All regional, national and international registries that are part of the TGDOC are governed by a Charter. It outlines the relationship of the individual registries with TGDOC, and defines the basic requirements for registries to become and remain a TGDOC registry. It also defines the relationship of the TGDOC with third parties (such as industry and academic partners who wish to use the Global Registries Network for research or clinical trials).  The Charter is an integral part of agreements and contracts related to and involving the Global Registries Network. 

 The TGDOC Executive Board members: 

TGDOC

Anna Ambrosini

Anna Ambrosini

TGDOC Outgoing Chair

Anna Ambrosini has a PhD in Pharmacology and Toxicology. After having spent 15 years in research lab...

Michela Guglieri

Michela Guglieri

TGDOC Chair

Michela Guglieri, MD, is a Senior Clinical Lecturer and Consultant Neurologist at Newcastle Universi...

Miriam Rodrigues

Miriam Rodrigues

TGDOC Incoming Chair

Miriam Rodrigues is a genetic counsellor whose dedication to rare neuromuscular disorders began when...

Primary Sidebar

  • What We Do
  • Advisory Committee for Therapeutics
    • Advisory Committee for Therapeutics
    • Members of the Advisory Committee for Therapeutics
    • The Report
  • Global Registry Network
    • The Global Registry Network
    • Global Data systems Oversight Committee – TGDOC
    • Members of the Registry Network
  • Core Datasets
    • Core Datasets
    • DM dataset
    • DMD dataset
    • FSHD dataset
    • LGMD dataset
    • SMA dataset
  • Education
    • Education
    • Masterclasses
    • E-learning Platform
    • Endorsement of external programmes
  • Post-Marketing Surveillance
    • Post-Marketing Surveillance
    • STRIDE Registry

Footer

Contact us

4th Floor
The Catalyst
Newcastle upon Tyne
NE4 5TG
United Kingdom
info@treat-nmd.com

Links

Home
Who we are
What we do
Who we support
Resources & support
Connect with us
Privacy Policy
Cookies

Newsletter sign up

Connect

info@treat-nmd.com
TREAT NMD © 2023
Privacy Policy
Sitemap
STCS LTD

  • Home
  • Who We Are
    • About Us
    • Partnerships and Collaborations
    • Governance
    • Our Team
    • Back
  • Who We Support
    • Patients
    • Clinicians / Researchers
    • Life Sciences Industry
    • Back
  • What We Do
    • Advisory Committee for Therapeutics
      • Members of the Advisory Committee for Therapeutics
      • Take Part in TACT
      • The Report
      • Back
    • The Global Registry Network
      • Members of the Registry Network
      • Back
    • Core Datasets
      • DM dataset
      • DMD dataset
      • FSHD dataset
      • LGMD
      • SMA
      • Back
    • Education
      • Masterclasses
      • E-learning Platform
      • Endorsement of External Programmes
      • Back
    • Post-Marketing Surveillance
    • Back
  • Resources and Support
    • Neuromuscular Disease Information
      • Becker muscular dystrophy
      • Charcot-Marie-Tooth
      • Congenital muscular dystrophy
      • Congenital myasthenic syndromes
      • Duchenne muscular dystrophy
      • Facioscapulohumeral muscular dystrophy
      • GNE myopathy
      • Limb girdle muscular dystrophy
      • Myotonic dystrophy
      • Myotubular and centronuclear myopathies
      • Spinal muscular atrophy
      • Back
    • Research Overview
      • DMD
        • Gene Therapy for DMD
        • Mutation Specific Approaches
        • Cell Therapy
        • Drug Therapy
        • Back
      • Back
    • Standards of Care & Family Guides
      • CM Care
      • CMD Care
      • DM Care
      • DMD Care
      • FSHD Care
      • SMA Care
      • Back
    • SOP Library
      • MDX Mouse (DMD)
      • GRMD Dog (DMD)
      • CMD Mouse (CMD)
      • SMA Mouse (SMA)
      • CMD animal models
      • MDC1A Preclinical Research
      • Cell Lines
        • Clinical Outcome Measures
        • Functional Evaluation Tools
        • NMR (MRI/MRS) Imaging
        • Muscle Biopsy
        • Back
      • Back
    • Social and Ethical Issues
    • Back
  • Connect With Us
    • News
    • Events
    • Submit an Event
    • Newsletter Sign-up
    • Network Membership
    • Contact Us
    • Back